Browsing Tag
Eli Lilly
48 posts
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Mangoceuticals lands breakthrough partnership with Eli Lilly and Novo Nordisk to deliver low-cost GLP-1 care
Find out how Mangoceuticals’ partnership with Eli Lilly and Novo Nordisk could transform affordable access to Zepbound and Wegovy obesity treatments.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Are Novo Nordisk layoffs, FDA scrutiny of Hims & Hers, and UnitedHealth profit squeeze reshaping the healthcare sector?
Novo Nordisk layoffs, Hims & Hers FDA warning, and UnitedHealth earnings headwinds shake the healthcare sector. See what investors need to know.